Navigation Links
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Date:6/2/2009

Forward-looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the ability of fidaxomicin to address current treatment limitations and the presentation of future clinical trial results. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and status of its preclinical and clinical development of potential drugs and other risks detailed in Optimer's filings with the Securities and Exchange Commission. 

    Contacts

    Optimer Pharmaceuticals, Inc.
    John Prunty, CFO & VP, Finance
    Christina Donaghy, Corporate Communications Manager
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 Kitware , ... announces a new Fast-Track award from the U.S. Department ... environment (IDAE) for the nuclear power industry. , Construction ... more than 30 years, but the United States’ nuclear ... gains in power plant utilization through improved refueling, maintenance, ...
(Date:6/17/2013)... Belvoir, VA (PRWEB) June 17, 2013 ... annual Basic Research Technical Review at the Waterford in ... More than 300 grant awardees will present technical details ... Technical sessions will cover a broad range of counter ... (2) Cognitive, Information and Network Science; (3) Science for ...
(Date:6/17/2013)... (PRWEB) June 17, 2013 With the huge ... launch of the Chief Medical Officer Summit for Emerging Life ... will take place in San Francisco on November 4-5, 2013 ... the first time, West Coast Chief Medical Officers at biotechs ... Elizabeth Stoner, Managing Director of MPM Capital. Valerie Bowling, Executive ...
(Date:6/17/2013)... June 17, 2013 ... announced the addition of the "North ... Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables ... Free & Auto Injectors] & Therapeutics- Forecasts ... ,      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
Breaking Biology Technology:Kitware to Develop an Open-Source HPC Design-Analysis Environment for Nuclear Energy Research 2Invitation to Register: Annual Defense Threat Reduction Agency Basic Research Technical Review 2Chief Medical Officer Summit for Biotechs Goes West 2Chief Medical Officer Summit for Biotechs Goes West 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3
... 2010 (BRONX, NY) By constructing a microscope ... cells, researchers at Albert Einstein College of Medicine ... that occur during one of the most important "trips" ... Ribonucleic acid (RNA) molecules from the nucleus into the ...
... Therapies, Inc., (VTI) is pleased to announce that ... in Riyadh, Kingdom of Saudi Arabia (K.S.A.) in the further ... L i VER Failure) clinical trial to the ... therapy product, ELAD®, can prevent deterioration of liver function and ...
... BASKING RIDGE, N.J., Sept. 16 Regado Biosciences, a ... with active control agents, announced that David J. Mazzo, ... UBS Global Life Sciences Conference.  Dr. Mazzo,s presentation will ... York City on Wednesday, September 22, 2010 at 8:00 ...
Cached Biology Technology:Nature study shows how molecules escape from the nucleus 2Nature study shows how molecules escape from the nucleus 3Vital Therapies Expands SILVER Trial to Saudi Arabia 2Vital Therapies Expands SILVER Trial to Saudi Arabia 3Vital Therapies Expands SILVER Trial to Saudi Arabia 4Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City 2Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City 3
(Date:6/17/2013)... An international team led by scientists at The Scripps ... Albert Einstein College of Medicine of Yeshiva University has ... the tuberculosis (TB) bacterium in two different ways. , ... of the major global health crises of our timethe ... Peter G. Schultz, the Scripps Family Chair Professor of ...
(Date:6/17/2013)... understand the concept of improving original foundations with more ... the University of Pittsburgh,s Kenneth P. Dietrich School of ... that could make drug delivery, gas storage, and gas ... findings were reported in the latest issue of the ... JACS ). , The recent work builds upon Pitt ...
(Date:6/17/2013)... Kansas State University research associate has received a prestigious ... to prevent the spread of malaria. , Bart Bryant, ... of Health,s National Research Service Award Individual Postdoctoral Fellowship, ... seventh Kansas State University researcher to receive the award ... hold such an award. , Bryant, a university doctoral ...
Breaking Biology News(10 mins):New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4'Chemical architects' build materials with potential applications in drug delivery and gas storage 2NIH fellowship helps researcher fight malaria, understand mosquito immunity 2
... Detects Faces in Motion, Matches with Watch-list ... Lithuania, March 9 Neurotechnology, a provider ... the availability of VeriLook Surveillance SDK, a ... using live video streams from high-resolution digital ...
... Va., March 10 CEL-SCI Corporation (NYSE Alternext US: ... launch a new manufacturing process that could allow drugs ... maintain their potency and thereby potentially also their shelf ... by CEL-SCI may also significantly accelerate the time to ...
... March 19 during 12 p.m. Advertising Research Foundation ... (R), a revolutionary media research firm, recently conducted ... Foundation (ARF) conference and provided attendees with same-day ... comprise impactful presentations. Results of the study, which ...
Cached Biology News:VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 2VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 3CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 3CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 4Innerscope Research(R) Uses Same-Day Results From Biometric Study to Identify Key Themes, Styles Behind Effective, Engaging Speaker Presentations 2
ANTI L-DOPA...
The Light Diagnostics Calicivirus Genotype 1&2 Typing OligoDetect assay is applicable for the qualitative detection of calicivirus RNA generated by an in-house validated in vitro nucleic acid amplifi...
Recombinant Rat CINC-2 alpha, CF...
sodium channel, nonvoltage-gated 1 alpha,...
Biology Products: